25 XP   0   0   10

Halozyme Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Halozyme together

PenkeI guess you are interested in Halozyme Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Halozyme Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Halozyme Therapeutics Inc

I send you an email if I find something interesting about Halozyme Therapeutics Inc.

Quick analysis of Halozyme (30 sec.)










What can you expect buying and holding a share of Halozyme? (30 sec.)

How much money do you get?

How much money do you get?
$0.20
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$0.62
Expected worth in 1 year
$0.02
How sure are you?
57.5%

+ What do you gain per year?

Total Gains per Share
$-0.40
Return On Investment
-1.0%

For what price can you sell your share?

Current Price per Share
$40.73
Expected price per share
$36.94 - $43.33
How sure are you?
50%

1. Valuation of Halozyme (5 min.)




Live pricePrice per Share (EOD)

$40.73

Intrinsic Value Per Share

$16.44 - $41.33

Total Value Per Share

$17.06 - $41.95

2. Growth of Halozyme (5 min.)




Is Halozyme growing?

Current yearPrevious yearGrowGrow %
How rich?$83.8m$205m-$67.5m-49.2%

How much money is Halozyme making?

Current yearPrevious yearGrowGrow %
Making money$70.3m$50.5m$19.8m28.2%
Net Profit Margin33.3%31.9%--

How much money comes from the company's main activities?

3. Financial Health of Halozyme (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#412 / 1031

Most Revenue
#54 / 1031

Most Profit
#32 / 1031

Most Efficient
#54 / 1031

What can you expect buying and holding a share of Halozyme? (5 min.)

Welcome investor! Halozyme's management wants to use your money to grow the business. In return you get a share of Halozyme.

What can you expect buying and holding a share of Halozyme?

First you should know what it really means to hold a share of Halozyme. And how you can make/lose money.

Speculation

The Price per Share of Halozyme is $40.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Halozyme.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Halozyme, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.62. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Halozyme.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.641.6%0.521.3%0.360.9%0.330.8%0.120.3%
Usd Book Value Change Per Share-1.23-3.0%-0.15-0.4%-0.04-0.1%-0.06-0.1%0.020.0%
Usd Dividend Per Share0.100.2%0.050.1%0.000.0%0.481.2%0.240.6%
Usd Total Gains Per Share-1.13-2.8%-0.10-0.2%-0.04-0.1%0.421.0%0.260.6%
Usd Price Per Share36.96-37.36-45.08-33.90-23.99-
Price to Earnings Ratio14.52-19.88-37.23-27.98-15.45-
Price-to-Total Gains Ratio-32.61-4.08-90.71-64.38-43.90-
Price to Book Ratio59.18-47.90-36.57-37.38-28.52-
Price-to-Total Gains Ratio-32.61-4.08-90.71-64.38-43.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share40.73
Number of shares24
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.48
Usd Book Value Change Per Share-0.15-0.06
Usd Total Gains Per Share-0.100.42
Gains per Quarter (24 shares)-2.4110.17
Gains per Year (24 shares)-9.6640.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
15-14-2046-531
210-29-3092-1172
314-43-40138-16113
419-58-50184-21154
524-72-60230-26195
629-86-70276-32236
733-101-80322-37277
838-115-90368-42318
943-130-100414-48359
1048-144-110459-53400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%16.04.00.080.0%20.020.00.050.0%23.065.00.026.1%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%11.09.00.055.0%20.020.00.050.0%34.054.00.038.6%
Dividend per Share2.00.02.050.0%4.00.08.033.3%6.00.014.030.0%6.00.034.015.0%6.00.082.06.8%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%14.06.00.070.0%23.017.00.057.5%37.051.00.042.0%

Fundamentals of Halozyme

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-03-20 19:48:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Halozyme Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Halozyme earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • A Net Profit Margin of 37.1% means that $0.37 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Halozyme Therapeutics Inc:

  • The MRQ is 37.1%. The company is making a huge profit. +2
  • The TTM is 33.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ37.1%TTM33.3%+3.8%
TTM33.3%YOY31.9%+1.5%
TTM33.3%5Y29.9%+3.4%
5Y29.9%10Y-18.5%+48.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ37.1%-171.8%+208.9%
TTM33.3%-205.8%+239.1%
YOY31.9%-262.1%+294.0%
5Y29.9%-455.6%+485.5%
10Y-18.5%-589.0%+570.5%
1.1.2. Return on Assets

Shows how efficient Halozyme is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • 4.9% Return on Assets means that Halozyme generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Halozyme Therapeutics Inc:

  • The MRQ is 4.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.9%TTM3.9%+1.0%
TTM3.9%YOY3.2%+0.7%
TTM3.9%5Y3.6%+0.3%
5Y3.6%10Y-1.0%+4.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9%-12.5%+17.4%
TTM3.9%-12.2%+16.1%
YOY3.2%-11.2%+14.4%
5Y3.6%-13.4%+17.0%
10Y-1.0%-14.7%+13.7%
1.1.3. Return on Equity

Shows how efficient Halozyme is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • 101.9% Return on Equity means Halozyme generated $1.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Halozyme Therapeutics Inc:

  • The MRQ is 101.9%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 61.1%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ101.9%TTM61.1%+40.8%
TTM61.1%YOY32.1%+29.0%
TTM61.1%5Y32.4%+28.7%
5Y32.4%10Y1.4%+31.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ101.9%-15.8%+117.7%
TTM61.1%-15.7%+76.8%
YOY32.1%-13.9%+46.0%
5Y32.4%-18.3%+50.7%
10Y1.4%-19.2%+20.6%

1.2. Operating Efficiency of Halozyme Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Halozyme is operating .

  • Measures how much profit Halozyme makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • An Operating Margin of 43.9% means the company generated $0.44  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Halozyme Therapeutics Inc:

  • The MRQ is 43.9%. The company is operating very efficient. +2
  • The TTM is 40.2%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ43.9%TTM40.2%+3.7%
TTM40.2%YOY41.9%-1.8%
TTM40.2%5Y29.7%+10.5%
5Y29.7%10Y-14.2%+43.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ43.9%-299.1%+343.0%
TTM40.2%-210.1%+250.3%
YOY41.9%-279.7%+321.6%
5Y29.7%-459.9%+489.6%
10Y-14.2%-596.9%+582.7%
1.2.2. Operating Ratio

Measures how efficient Halozyme is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.56 means that the operating costs are $0.56 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Halozyme Therapeutics Inc:

  • The MRQ is 0.561. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.598. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.561TTM0.598-0.037
TTM0.598YOY0.581+0.018
TTM0.5985Y0.701-0.103
5Y0.70110Y1.140-0.439
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5612.861-2.300
TTM0.5983.193-2.595
YOY0.5813.615-3.034
5Y0.7015.560-4.859
10Y1.1407.396-6.256

1.3. Liquidity of Halozyme Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Halozyme is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.64 means the company has $6.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Halozyme Therapeutics Inc:

  • The MRQ is 6.635. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.884. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.635TTM6.884-0.249
TTM6.884YOY5.798+1.086
TTM6.8845Y7.532-0.648
5Y7.53210Y5.997+1.535
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.6353.986+2.649
TTM6.8844.440+2.444
YOY5.7985.552+0.246
5Y7.5326.158+1.374
10Y5.9976.492-0.495
1.3.2. Quick Ratio

Measures if Halozyme is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • A Quick Ratio of 7.00 means the company can pay off $7.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Halozyme Therapeutics Inc:

  • The MRQ is 7.003. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.042. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.003TTM7.042-0.039
TTM7.042YOY6.950+0.092
TTM7.0425Y9.560-2.518
5Y9.56010Y8.004+1.556
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0033.638+3.365
TTM7.0424.168+2.874
YOY6.9505.515+1.435
5Y9.5606.012+3.548
10Y8.0046.209+1.795

1.4. Solvency of Halozyme Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Halozyme assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Halozyme to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.95 means that Halozyme assets are financed with 95.2% credit (debt) and the remaining percentage (100% - 95.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Halozyme Therapeutics Inc:

  • The MRQ is 0.952. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.924. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.952TTM0.924+0.027
TTM0.924YOY0.867+0.058
TTM0.9245Y0.787+0.137
5Y0.78710Y0.775+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9520.335+0.617
TTM0.9240.330+0.594
YOY0.8670.267+0.600
5Y0.7870.367+0.420
10Y0.7750.378+0.397
1.4.2. Debt to Equity Ratio

Measures if Halozyme is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Halozyme to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,968.1% means that company has $19.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Halozyme Therapeutics Inc:

  • The MRQ is 19.681. The company is unable to pay all its debts with equity. -1
  • The TTM is 15.518. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ19.681TTM15.518+4.163
TTM15.518YOY9.153+6.365
TTM15.5185Y7.645+7.873
5Y7.64510Y5.707+1.939
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.6810.376+19.305
TTM15.5180.398+15.120
YOY9.1530.334+8.819
5Y7.6450.429+7.216
10Y5.7070.476+5.231

2. Market Valuation of Halozyme Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Halozyme generates.

  • Above 15 is considered overpriced but always compare Halozyme to the Biotechnology industry mean.
  • A PE ratio of 14.52 means the investor is paying $14.52 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Halozyme Therapeutics Inc:

  • The EOD is 16.003. Based on the earnings, the company is fair priced.
  • The MRQ is 14.522. Based on the earnings, the company is underpriced. +1
  • The TTM is 19.878. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD16.003MRQ14.522+1.481
MRQ14.522TTM19.878-5.356
TTM19.878YOY37.230-17.351
TTM19.8785Y27.977-8.099
5Y27.97710Y15.452+12.525
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD16.003-2.643+18.646
MRQ14.522-2.418+16.940
TTM19.878-2.742+22.620
YOY37.230-4.123+41.353
5Y27.977-6.257+34.234
10Y15.452-6.478+21.930
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Halozyme Therapeutics Inc:

  • The EOD is 13.698. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 12.430. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 14.332. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD13.698MRQ12.430+1.268
MRQ12.430TTM14.332-1.902
TTM14.332YOY28.578-14.246
TTM14.3325Y24.810-10.478
5Y24.81010Y0.863+23.947
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.698-3.244+16.942
MRQ12.430-2.939+15.369
TTM14.332-3.478+17.810
YOY28.578-5.592+34.170
5Y24.810-8.473+33.283
10Y0.863-8.881+9.744
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Halozyme is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 59.18 means the investor is paying $59.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Halozyme Therapeutics Inc:

  • The EOD is 65.219. Based on the equity, the company is expensive. -2
  • The MRQ is 59.182. Based on the equity, the company is expensive. -2
  • The TTM is 47.901. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD65.219MRQ59.182+6.037
MRQ59.182TTM47.901+11.280
TTM47.901YOY36.565+11.336
TTM47.9015Y37.383+10.518
5Y37.38310Y28.523+8.860
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD65.2192.124+63.095
MRQ59.1822.041+57.141
TTM47.9012.118+45.783
YOY36.5652.915+33.650
5Y37.3833.682+33.701
10Y28.5234.114+24.409
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Halozyme Therapeutics Inc.

3.1. Institutions holding Halozyme Therapeutics Inc

Institutions are holding 100.107% of the shares of Halozyme Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc14.69030.0176186309635123482.8277
2023-09-30Vanguard Group Inc10.33440.012313106644-29621-0.2255
2023-12-31Artisan Partners Limited Partnership5.27430.38076689058-1023816-13.2741
2023-09-30State Street Corporation4.89610.01326209531-294770-4.5319
2023-12-31Snyder Capital Management LP2.9253.22073709599-614633-14.2137
2023-09-30Macquarie Group Ltd2.71570.165334441901348354.0744
2023-09-30AllianceBernstein L.P.2.64680.054533567762534052308.0075
2023-09-30JPMorgan Chase & Co2.49420.01333163265-331830-9.4942
2023-09-30Geode Capital Management, LLC2.19780.01272787349570812.0907
2023-09-30GW&K Investment Management, LLC1.84850.89972344305-35284-1.4828
2023-12-31Amvescap Plc.1.60110.01792030634136120.6749
2023-09-30Northern Trust Corp1.58340.01492008156-15056-0.7442
2023-12-31TD Asset Management Inc1.56430.072119839161662390517.0313
2023-12-31Thrivent Financial For Lutherans1.51520.15481921659-92574-4.596
2023-09-30Goldman Sachs Group Inc1.3660.0133173240516664910.6434
2023-09-30Charles Schwab Investment Management Inc1.33910.01861698359159020.9452
2023-12-31Dimensional Fund Advisors, Inc.1.27190.017416131131458799.9424
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.24270.6431576083483703.1662
2023-09-30Nuveen Asset Management, LLC1.21810.0208154484618214113.3661
2023-12-31Stephens Inv Mgmt Group LLC1.19730.82041518455637484.3822
Total 63.92226.583281069306+3099423+3.8%

3.2. Funds holding Halozyme Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.2650.01064140808-10661-0.2568
2024-02-29iShares Core S&P Mid-Cap ETF3.17080.19874021340-11579-0.2871
2024-02-29Vanguard Small Cap Index2.68480.09653405021316490.9382
2024-02-29iShares Russell 2000 ETF2.47810.20063142825-514-0.0164
2024-01-31Aviva Investors GlConvtAbsRet I USD Acc2.02420256713625671360
2023-12-31Artisan Small Cap Investor1.85015.15332346361-128612-5.1965
2023-12-31Artisan U.S. Small-Cap Growth1.85015.12792346361-128612-5.1965
2024-02-29SPDR® S&P Biotech ETF1.66551.06192112275394801.9047
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.53950.0762195252115110.0774
2024-02-29Vanguard Small Cap Growth Index Inv1.50760.21811912019304291.6172
2023-12-31Macquarie US Small Cap Core Equity1.43270.8984181698200
2024-01-31Delaware Small Cap Core I1.41570.85891795459-21523-1.1845
2023-12-31Vanguard Explorer Inv1.17620.25781491687508373.5283
2023-12-31Fidelity Small Cap Index1.01750.18771290478154651.2129
2024-02-29First Trust NYSE Arca Biotech ETF0.90843.889115210000
2024-02-29iShares Russell 2000 Growth ETF0.89860.3996113966915210.1336
2024-01-31JPMorgan Small Cap Growth A0.88161.04961118084-32688-2.8405
2024-02-29SPDR® S&P MIDCAP 400 ETF Trust0.83190.1998105507439720.3779
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.79610.47891009700-118800-10.5272
2024-02-29iShares Biotechnology ETF0.78830.5233999766-4500-0.4481
Total 32.182720.886840815666+2284511+5.6%

3.3. Insider Transactions

Insiders are holding 1.071% of the shares of Halozyme Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-12Michael J LabarreSELL1000041.64
2024-02-28Michael J LabarreSELL1000039.55
2023-12-12Michael J LabarreSELL1000039.63
2023-10-17Michael J LabarreSELL1000036.52
2023-09-19Michael J LabarreSELL1000039.1
2023-08-31Helen TorleySELL1000042.82
2023-08-29Helen TorleySELL1000042.4
2023-08-22Michael J LabarreSELL1000042.41
2023-08-22Michael J LabarreSELL1000042.41
2023-08-17Helen TorleySELL1000043.18
2023-08-14James M DalySELL1000043.74
2023-08-11James M DalySELL1000043.71
2023-07-26Helen TorleySELL1000042.69
2023-07-18Michael J LabarreSELL1000040.43
2023-06-21Michael J LabarreSELL1000036
2023-04-18Michael J LabarreSELL1000036

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Halozyme Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.234-0.150-88%-0.035-97%-0.055-96%0.020-6413%
Book Value Per Share--0.6251.023-39%1.456-57%1.164-46%0.876-29%
Current Ratio--6.6356.884-4%5.798+14%7.532-12%5.997+11%
Debt To Asset Ratio--0.9520.924+3%0.867+10%0.787+21%0.775+23%
Debt To Equity Ratio--19.68115.518+27%9.153+115%7.645+157%5.707+245%
Dividend Per Share--0.1000.050+103%-+100%0.479-79%0.239-58%
Eps--0.6360.523+22%0.361+76%0.334+90%0.123+419%
Free Cash Flow Per Share--0.7430.692+7%0.420+77%0.312+139%0.141+429%
Free Cash Flow To Equity Per Share---1.119-0.059-95%1.057-206%0.330-439%0.218-614%
Gross Profit Margin--1.0001.0000%1.0000%0.998+0%0.999+0%
Intrinsic Value_10Y_max--41.328--------
Intrinsic Value_10Y_min--16.437--------
Intrinsic Value_1Y_max--2.452--------
Intrinsic Value_1Y_min--0.751--------
Intrinsic Value_3Y_max--8.654--------
Intrinsic Value_3Y_min--3.046--------
Intrinsic Value_5Y_max--16.409--------
Intrinsic Value_5Y_min--6.189--------
Market Cap5174909420.000+4%4959921120.0005041297182.500-2%6322347410.000-22%4793022197.000+3%3345064509.000+48%
Net Profit Margin--0.3710.333+11%0.319+17%0.299+24%-0.185+150%
Operating Margin--0.4390.402+9%0.419+5%0.297+48%-0.142+132%
Operating Ratio--0.5610.598-6%0.581-3%0.701-20%1.140-51%
Pb Ratio65.219+9%59.18247.901+24%36.565+62%37.383+58%28.523+107%
Pe Ratio16.003+9%14.52219.878-27%37.230-61%27.977-48%15.452-6%
Price Per Share40.730+9%36.96037.355-1%45.080-18%33.902+9%23.993+54%
Price To Free Cash Flow Ratio13.698+9%12.43014.332-13%28.578-57%24.810-50%0.863+1340%
Price To Total Gains Ratio-35.935-10%-32.6094.083-899%90.712-136%64.384-151%43.896-174%
Quick Ratio--7.0037.042-1%6.950+1%9.560-27%8.004-13%
Return On Assets--0.0490.039+25%0.032+53%0.036+37%-0.010+120%
Return On Equity--1.0190.611+67%0.321+217%0.324+215%0.014+7436%
Total Gains Per Share---1.133-0.101-91%-0.035-97%0.424-368%0.259-538%
Usd Book Value--83808000.000137468000.000-39%205054000.000-59%165346450.000-49%123919850.000-32%
Usd Book Value Change Per Share---1.234-0.150-88%-0.035-97%-0.055-96%0.020-6413%
Usd Book Value Per Share--0.6251.023-39%1.456-57%1.164-46%0.876-29%
Usd Dividend Per Share--0.1000.050+103%-+100%0.479-79%0.239-58%
Usd Eps--0.6360.523+22%0.361+76%0.334+90%0.123+419%
Usd Free Cash Flow--99758000.00093319250.000+7%58825000.000+70%43502350.000+129%20168450.000+395%
Usd Free Cash Flow Per Share--0.7430.692+7%0.420+77%0.312+139%0.141+429%
Usd Free Cash Flow To Equity Per Share---1.119-0.059-95%1.057-206%0.330-439%0.218-614%
Usd Market Cap5174909420.000+4%4959921120.0005041297182.500-2%6322347410.000-22%4793022197.000+3%3345064509.000+48%
Usd Price Per Share40.730+9%36.96037.355-1%45.080-18%33.902+9%23.993+54%
Usd Profit--85388000.00070398500.000+21%50532250.000+69%47163900.000+81%18057250.000+373%
Usd Revenue--230039000.000207313250.000+11%165029000.000+39%119813250.000+92%80545550.000+186%
Usd Total Gains Per Share---1.133-0.101-91%-0.035-97%0.424-368%0.259-538%
 EOD+3 -5MRQTTM+17 -18YOY+19 -165Y+18 -1810Y+18 -18

4.2. Fundamental Score

Let's check the fundamental score of Halozyme Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1516.003
Price to Book Ratio (EOD)Between0-165.219
Net Profit Margin (MRQ)Greater than00.371
Operating Margin (MRQ)Greater than00.439
Quick Ratio (MRQ)Greater than17.003
Current Ratio (MRQ)Greater than16.635
Debt to Asset Ratio (MRQ)Less than10.952
Debt to Equity Ratio (MRQ)Less than119.681
Return on Equity (MRQ)Greater than0.151.019
Return on Assets (MRQ)Greater than0.050.049
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Halozyme Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.488
Ma 20Greater thanMa 5040.882
Ma 50Greater thanMa 10037.825
Ma 100Greater thanMa 20037.923
OpenGreater thanClose40.510
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Current Deferred Revenue 3,24603,246-2,404842-175667-32,864-32,197



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,733,270
Total Liabilities1,649,462
Total Stockholder Equity83,808
 As reported
Total Liabilities 1,649,462
Total Stockholder Equity+ 83,808
Total Assets = 1,733,270

Assets

Total Assets1,733,270
Total Current Assets746,424
Long-term Assets986,846
Total Current Assets
Cash And Cash Equivalents 118,370
Short-term Investments 217,630
Net Receivables 234,210
Inventory 127,601
Other Current Assets 48,613
Total Current Assets  (as reported)746,424
Total Current Assets  (calculated)746,424
+/-0
Long-term Assets
Property Plant Equipment 74,944
Goodwill 416,821
Intangible Assets 472,879
Long-term Assets Other 17,816
Long-term Assets  (as reported)986,846
Long-term Assets  (calculated)982,460
+/- 4,386

Liabilities & Shareholders' Equity

Total Current Liabilities112,494
Long-term Liabilities1,536,968
Total Stockholder Equity83,808
Total Current Liabilities
Short-term Debt 32,197
Accounts payable 11,816
Other Current Liabilities 100,678
Total Current Liabilities  (as reported)112,494
Total Current Liabilities  (calculated)144,691
+/- 32,197
Long-term Liabilities
Long term Debt 1,499,248
Long-term Liabilities Other 37,720
Long-term Liabilities  (as reported)1,536,968
Long-term Liabilities  (calculated)1,536,968
+/-0
Total Stockholder Equity
Common Stock127
Retained Earnings 90,550
Accumulated Other Comprehensive Income -9,278
Other Stockholders Equity 2,409
Total Stockholder Equity (as reported)83,808
Total Stockholder Equity (calculated)83,808
+/-0
Other
Capital Stock127
Cash and Short Term Investments 336,000
Common Stock Shares Outstanding 134,197
Current Deferred Revenue-32,197
Liabilities and Stockholders Equity 1,733,270
Net Debt 1,380,878
Net Invested Capital 1,583,056
Net Working Capital 633,930
Property Plant and Equipment Gross 94,605
Short Long Term Debt Total 1,499,248



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-31
> Total Assets 
38
148
137
97
92
77
68
48
7,733
6,209
3,785
16,404
13,877
10,938
7,385
20,510
18,972
16,842
17,812
46,091
73,867
104,127
109,993
103,460
98,872
88,556
80,753
76,563
68,927
96,296
86,109
77,150
65,163
51,486
100,392
91,345
80,933
89,509
78,243
65,759
134,719
121,748
107,982
134,728
116,866
107,387
110,145
101,793
197,687
182,052
164,626
165,977
159,125
174,047
158,734
181,789
309,096
296,127
282,498
261,515
226,767
344,786
357,149
519,945
495,469
474,754
444,507
440,248
429,109
417,830
370,356
565,874
492,353
526,997
524,029
579,924
966,582
1,025,863
1,185,420
1,104,429
1,162,248
1,781,390
1,864,543
1,841,511
1,699,447
1,810,440
1,892,662
1,733,270
1,733,2701,892,6621,810,4401,699,4471,841,5111,864,5431,781,3901,162,2481,104,4291,185,4201,025,863966,582579,924524,029526,997492,353565,874370,356417,830429,109440,248444,507474,754495,469519,945357,149344,786226,767261,515282,498296,127309,096181,789158,734174,047159,125165,977164,626182,052197,687101,793110,145107,387116,866134,728107,982121,748134,71965,75978,24389,50980,93391,345100,39251,48665,16377,15086,10996,29668,92776,56380,75388,55698,872103,460109,993104,12773,86746,09117,81216,84218,97220,5107,38510,93813,87716,4043,7856,2097,733486877929713714838
   > Total Current Assets 
38
123
112
97
92
73
66
48
7,569
6,028
3,611
16,146
13,540
10,546
6,937
20,106
18,582
16,454
17,332
45,594
73,295
102,944
108,076
101,177
96,621
86,116
78,229
74,013
66,181
93,649
83,406
74,442
62,677
49,324
98,431
89,498
79,192
88,013
76,969
63,987
132,566
119,731
105,619
131,028
111,110
100,421
102,818
95,195
190,914
175,623
158,600
161,321
153,329
168,442
153,090
171,772
297,035
284,344
272,605
256,532
222,354
340,834
353,345
510,372
484,470
462,032
429,926
427,849
409,036
391,706
342,041
543,436
467,971
500,358
498,895
554,764
941,719
999,750
1,017,299
926,287
988,689
541,938
653,201
739,013
615,019
765,745
879,006
746,424
746,424879,006765,745615,019739,013653,201541,938988,689926,2871,017,299999,750941,719554,764498,895500,358467,971543,436342,041391,706409,036427,849429,926462,032484,470510,372353,345340,834222,354256,532272,605284,344297,035171,772153,090168,442153,329161,321158,600175,623190,91495,195102,818100,421111,110131,028105,619119,731132,56663,98776,96988,01379,19289,49898,43149,32462,67774,44283,40693,64966,18174,01378,22986,11696,621101,177108,076102,94473,29545,59417,33216,45418,58220,1066,93710,54613,54016,1463,6116,0287,569486673929711212338
       Cash And Cash Equivalents 
14
122
112
97
73
69
63
48
7,453
5,940
3,480
16,008
13,130
10,060
6,636
19,132
17,571
15,100
16,101
44,189
70,971
100,595
105,115
97,679
92,558
82,410
72,493
63,716
62,065
89,241
77,636
67,465
55,176
41,312
89,841
83,256
73,829
79,117
66,329
52,826
116,608
102,042
87,615
99,901
39,018
27,928
17,492
27,357
76,570
56,135
46,375
61,389
44,287
67,769
71,514
43,292
69,093
61,233
61,207
66,764
45,188
114,745
164,397
168,740
98,012
55,173
55,019
57,936
60,595
67,041
59,202
120,179
104,820
133,606
65,741
147,703
499,450
446,966
491,683
118,719
117,835
90,932
147,159
234,195
96,383
221,165
274,227
118,370
118,370274,227221,16596,383234,195147,15990,932117,835118,719491,683446,966499,450147,70365,741133,606104,820120,17959,20267,04160,59557,93655,01955,17398,012168,740164,397114,74545,18866,76461,20761,23369,09343,29271,51467,76944,28761,38946,37556,13576,57027,35717,49227,92839,01899,90187,615102,042116,60852,82666,32979,11773,82983,25689,84141,31255,17667,46577,63689,24162,06563,71672,49382,41092,55897,679105,115100,59570,97144,18916,10115,10017,57119,1326,63610,06013,13016,0083,4805,9407,453486369739711212214
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,408
48,083
47,819
44,146
87,919
91,513
88,089
74,234
84,212
72,946
52,204
65,047
169,545
168,757
159,845
138,217
133,797
182,788
152,525
300,474
335,682
343,721
309,347
296,590
268,122
220,424
178,796
301,083
263,363
251,840
280,965
220,310
264,856
308,343
324,237
622,203
668,305
118,428
118,425
128,599
179,225
127,110
209,055
217,630
217,630209,055127,110179,225128,599118,425118,428668,305622,203324,237308,343264,856220,310280,965251,840263,363301,083178,796220,424268,122296,590309,347343,721335,682300,474152,525182,788133,797138,217159,845168,757169,54565,04752,20472,94684,21274,23488,08991,51387,91944,14647,81948,08348,40800000000000000000000000000000000000000000000
       Net Receivables 
24
0
0
0
2
3
3
0
0
0
0
0
0
68
41
414
120
401
384
533
553
402
417
780
1,130
1,161
1,496
7,264
477
893
1,590
4,244
2,021
2,254
2,622
2,328
1,731
4,496
6,238
2,262
5,551
5,687
4,464
15,703
10,376
10,832
24,522
9,097
10,956
12,895
8,275
9,149
7,725
9,738
8,392
32,410
25,543
23,227
17,679
15,680
12,452
14,473
14,695
22,133
26,574
33,582
27,656
30,005
28,164
32,219
40,744
59,442
29,749
37,401
62,551
97,730
88,391
153,196
112,099
90,975
113,762
189,368
233,302
231,072
194,883
246,179
217,325
234,210
234,210217,325246,179194,883231,072233,302189,368113,76290,975112,099153,19688,39197,73062,55137,40129,74959,44240,74432,21928,16430,00527,65633,58226,57422,13314,69514,47312,45215,68017,67923,22725,54332,4108,3929,7387,7259,1498,27512,89510,9569,09724,52210,83210,37615,7034,4645,6875,5512,2626,2384,4961,7312,3282,6222,2542,0214,2441,5908934777,2641,4961,1611,130780417402553533384401120414416800000033200024
       Other Current Assets 
0
0
0
0
17
0
0
0
116
88
130
86
363
387
215
281
605
539
613
428
1,296
1,327
1,831
2,015
2,253
1,896
3,715
2,591
3,072
2,712
2,942
1,574
4,321
4,676
4,892
3,721
3,383
4,317
4,298
8,332
8,910
10,218
11,353
12,753
10,571
11,112
9,139
8,426
8,704
7,966
8,945
10,143
9,623
10,266
9,879
21,534
22,509
20,372
21,022
21,248
16,627
13,656
12,397
13,879
19,809
21,152
19,619
20,693
20,914
28,122
27,248
33,373
28,587
29,240
31,941
28,274
30,679
32,691
33,302
40,482
41,026
45,595
51,039
45,024
37,007
38,885
49,478
48,613
48,61349,47838,88537,00745,02451,03945,59541,02640,48233,30232,69130,67928,27431,94129,24028,58733,37327,24828,12220,91420,69319,61921,15219,80913,87912,39713,65616,62721,24821,02220,37222,50921,5349,87910,2669,62310,1438,9457,9668,7048,4269,13911,11210,57112,75311,35310,2188,9108,3324,2984,3173,3833,7214,8924,6764,3211,5742,9422,7123,0722,5913,7151,8962,2532,0151,8311,3271,2964286135396052812153873638613088116000170000
   > Long-term Assets 
0
25
25
0
0
4
2
0
164
181
174
258
336
392
448
404
390
388
480
498
572
1,183
1,917
2,283
2,251
2,440
2,524
2,550
2,746
2,647
2,704
2,708
2,486
2,162
1,961
1,847
1,741
1,496
1,275
1,771
2,153
2,017
2,364
3,700
5,756
6,966
7,327
6,597
6,773
6,429
6,026
4,656
5,796
5,605
5,644
10,017
12,061
11,783
9,893
4,983
4,413
3,952
3,804
9,573
10,999
12,722
14,581
12,399
20,073
26,124
28,315
22,438
24,382
26,639
25,134
25,160
24,863
26,113
168,121
178,142
173,559
1,239,452
1,211,342
1,102,498
1,084,428
1,044,695
1,013,656
986,846
986,8461,013,6561,044,6951,084,4281,102,4981,211,3421,239,452173,559178,142168,12126,11324,86325,16025,13426,63924,38222,43828,31526,12420,07312,39914,58112,72210,9999,5733,8043,9524,4134,9839,89311,78312,06110,0175,6445,6055,7964,6566,0266,4296,7736,5977,3276,9665,7563,7002,3642,0172,1531,7711,2751,4961,7411,8471,9612,1622,4862,7082,7042,6472,7462,5502,5242,4402,2512,2831,9171,1835724984803883904044483923362581741811640240025250
       Property Plant Equipment 
0
0
0
0
0
0
0
0
151
168
159
236
316
371
425
381
367
369
461
498
572
1,183
1,917
2,283
2,251
2,440
2,524
2,550
2,746
2,647
2,704
2,708
2,486
2,162
1,961
1,847
1,741
1,496
1,275
1,771
2,153
2,017
2,364
3,700
3,975
4,577
4,936
3,422
3,628
3,343
3,249
2,951
2,732
2,594
2,686
3,943
4,440
4,682
4,407
4,264
3,741
3,330
3,232
3,520
4,937
4,789
6,790
7,465
14,542
15,079
15,398
10,855
11,752
11,169
10,252
10,593
10,366
10,132
9,588
8,794
8,513
37,091
36,674
75,570
77,964
74,559
74,669
74,944
74,94474,66974,55977,96475,57036,67437,0918,5138,7949,58810,13210,36610,59310,25211,16911,75210,85515,39815,07914,5427,4656,7904,7894,9373,5203,2323,3303,7414,2644,4074,6824,4403,9432,6862,5942,7322,9513,2493,3433,6283,4224,9364,5773,9753,7002,3642,0172,1531,7711,2751,4961,7411,8471,9612,1622,4862,7082,7042,6472,7462,5502,5242,4402,2512,2831,9171,18357249846136936738142537131623615916815100000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
199,481
199,481
409,049
416,223
416,821
416,821
416,821
416,821416,821416,821416,223409,049199,481199,481000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
976,097
948,904
546,652
528,817
510,982
490,641
472,879
472,879490,641510,982528,817546,652948,904976,097000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
13
13
15
23
21
21
23
23
23
19
19
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,781
2,390
2,391
3,176
3,145
3,086
2,777
1,705
3,064
3,011
2,958
6,074
7,621
7,101
5,486
719
672
622
572
6,053
6,062
7,933
7,791
4,934
5,531
11,045
12,917
11,583
12,630
15,470
14,882
14,567
14,497
15,981
158,533
169,348
165,046
26,783
26,283
71,227
0
42,333
31,525
0
031,52542,333071,22726,28326,783165,046169,348158,53315,98114,49714,56714,88215,47012,63011,58312,91711,0455,5314,9347,7917,9336,0626,0535726226727195,4867,1017,6216,0742,9583,0113,0641,7052,7773,0863,1453,1762,3912,3901,7810000000000000000000000000191923232321212315131300000000
> Total Liabilities 
5
3
5
10
14
5
5
37
773
1,294
1,991
1,579
1,928
1,715
1,812
2,303
2,693
2,426
2,757
23,010
32,963
33,372
45,080
45,692
49,601
48,902
49,867
61,183
65,003
69,861
69,509
70,246
68,355
65,603
65,388
70,994
67,418
69,456
51,188
54,858
53,658
52,514
56,792
85,875
85,185
96,244
113,631
121,783
130,939
126,753
124,686
124,625
121,580
123,818
126,935
138,790
279,624
286,207
294,490
293,996
285,266
286,621
284,760
311,579
230,405
219,829
204,769
191,361
169,062
157,778
125,003
474,109
434,311
421,420
425,041
428,877
898,987
906,115
903,746
907,476
901,992
1,488,219
1,767,552
1,671,713
1,633,597
1,659,407
1,643,481
1,649,462
1,649,4621,643,4811,659,4071,633,5971,671,7131,767,5521,488,219901,992907,476903,746906,115898,987428,877425,041421,420434,311474,109125,003157,778169,062191,361204,769219,829230,405311,579284,760286,621285,266293,996294,490286,207279,624138,790126,935123,818121,580124,625124,686126,753130,939121,783113,63196,24485,18585,87556,79252,51453,65854,85851,18869,45667,41870,99465,38865,60368,35570,24669,50969,86165,00361,18349,86748,90249,60145,69245,08033,37232,96323,0102,7572,4262,6932,3031,8121,7151,9281,5791,9911,29477337551410535
   > Total Current Liabilities 
5
3
5
10
14
5
5
37
773
1,294
1,991
1,579
1,928
1,715
1,812
2,303
2,693
2,426
2,757
4,251
5,156
6,001
8,261
8,864
9,603
9,409
11,062
14,218
13,330
15,168
15,813
14,397
13,761
11,062
11,781
15,343
12,604
31,543
13,792
17,302
16,681
16,148
21,039
18,946
19,751
32,833
39,624
25,453
36,360
31,721
34,593
24,331
26,209
35,039
44,851
62,457
64,223
38,885
52,660
54,585
61,708
82,615
102,048
131,328
119,224
132,429
139,119
149,361
138,662
135,417
108,041
85,637
42,002
26,073
26,976
421,385
107,421
114,251
113,153
117,147
111,691
199,512
109,384
130,789
91,919
116,393
115,185
112,494
112,494115,185116,39391,919130,789109,384199,512111,691117,147113,153114,251107,421421,38526,97626,07342,00285,637108,041135,417138,662149,361139,119132,429119,224131,328102,04882,61561,70854,58552,66038,88564,22362,45744,85135,03926,20924,33134,59331,72136,36025,45339,62432,83319,75118,94621,03916,14816,68117,30213,79231,54312,60415,34311,78111,06213,76114,39715,81315,16813,33014,21811,0629,4099,6038,8648,2616,0015,1564,2512,7572,4262,6932,3031,8121,7151,9281,5791,9911,29477337551410535
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,362
3,643
5,970
0
2,404
6,203
10,075
49,860
3,730
9,656
15,699
21,862
27,417
3,288
12,394
17,393
29,601
45,515
61,433
77,211
82,460
86,965
88,521
91,506
86,663
70,878
54,537
19,542
2,859
0
0
397,228
89,042
89,167
89,251
89,419
89,546
99,048
13,315
13,334
34,063
33,594
32,358
32,197
32,19732,35833,59434,06313,33413,31599,04889,54689,41989,25189,16789,042397,228002,85919,54254,53770,87886,66391,50688,52186,96582,46077,21161,43345,51529,60117,39312,3943,28827,41721,86215,6999,6563,73049,86010,0756,2032,40405,9703,6431,36200000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
49,860
0
0
0
21,862
27,417
3,288
12,394
17,393
29,601
211,032
61,433
77,211
82,460
86,965
88,521
91,506
86,663
70,878
54,537
19,542
2,859
0
0
397,228
89,042
89,167
89,251
89,419
89,546
99,048
13,315
13,334
0
0
0
0
000013,33413,31599,04889,54689,41989,25189,16789,042397,228002,85919,54254,53770,87886,66391,50688,52186,96582,46077,21161,433211,03229,60117,39312,3943,28827,41721,86200049,860000000000000000000000000000000000000000000000000000
       Accounts payable 
3
0
0
0
0
0
0
33
637
1,192
1,923
1,487
1,769
1,414
1,441
1,380
1,621
1,106
1,428
2,017
1,072
1,548
2,730
3,056
3,399
2,815
4,141
6,669
5,303
5,431
5,122
2,820
4,250
2,101
1,828
3,820
1,451
1,732
1,220
7,557
3,011
2,087
3,527
2,272
2,885
7,481
5,592
3,135
8,658
3,910
4,342
3,003
3,299
4,138
4,437
4,499
6,211
3,650
4,641
3,578
3,079
5,650
4,152
7,948
3,628
6,187
3,331
4,079
4,089
12,467
4,314
6,434
8,320
4,067
433
1,928
535
4,563
3,322
1,541
1,266
12,232
18,166
17,693
8,695
10,120
19,318
11,816
11,81619,31810,1208,69517,69318,16612,2321,2661,5413,3224,5635351,9284334,0678,3206,4344,31412,4674,0894,0793,3316,1873,6287,9484,1525,6503,0793,5784,6413,6506,2114,4994,4374,1383,2993,0034,3423,9108,6583,1355,5927,4812,8852,2723,5272,0873,0117,5571,2201,7321,4513,8201,8282,1014,2502,8205,1225,4315,3036,6694,1412,8153,3993,0562,7301,5481,0722,0171,4281,1061,6211,3801,4411,4141,7691,4871,9231,192637330000003
       Other Current Liabilities 
2
3
5
10
14
5
5
5
136
102
68
92
159
302
370
669
818
928
1,207
1,011
1,187
1,454
1,977
2,502
2,942
3,339
3,705
3,996
4,474
4,722
5,750
6,084
4,084
4,135
5,053
8,606
8,238
9,466
8,865
5,616
7,185
7,529
8,042
7,783
9,178
15,289
20,625
14,920
12,272
16,455
15,023
13,961
12,813
14,821
18,926
26,792
21,791
23,851
25,733
28,821
24,935
26,934
32,370
39,601
31,889
35,030
43,020
49,529
43,663
45,561
45,679
55,649
26,811
21,258
25,795
20,483
16,098
19,274
18,335
24,441
19,133
84,101
74,317
96,516
45,915
71,837
62,842
100,678
100,67862,84271,83745,91596,51674,31784,10119,13324,44118,33519,27416,09820,48325,79521,25826,81155,64945,67945,56143,66349,52943,02035,03031,88939,60132,37026,93424,93528,82125,73323,85121,79126,79218,92614,82112,81313,96115,02316,45512,27214,92020,62515,2899,1787,7838,0427,5297,1855,6168,8659,4668,2388,6065,0534,1354,0846,0845,7504,7224,4743,9963,7053,3392,9422,5021,9771,4541,1871,0111,20792881866937030215992681021365551410532
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,760
27,807
27,370
36,819
36,828
39,998
39,493
38,805
46,964
51,672
54,693
53,696
55,849
54,595
54,541
53,607
55,651
54,814
37,913
37,396
37,557
36,978
36,366
35,754
66,929
65,435
63,410
74,008
96,330
94,579
95,032
90,093
100,294
95,371
88,779
82,084
76,333
215,401
247,322
241,830
239,411
223,558
204,006
182,712
180,251
111,181
87,400
65,650
42,000
30,400
22,361
16,962
388,472
392,309
395,347
398,065
7,492
791,566
791,864
790,593
790,329
790,301
1,288,707
1,658,168
1,540,924
1,541,678
1,543,014
1,528,296
1,536,968
1,536,9681,528,2961,543,0141,541,6781,540,9241,658,1681,288,707790,301790,329790,593791,864791,5667,492398,065395,347392,309388,47216,96222,36130,40042,00065,65087,400111,181180,251182,712204,006223,558239,411241,830247,322215,40176,33382,08488,77995,371100,29490,09395,03294,57996,33074,00863,41065,43566,92935,75436,36636,97837,55737,39637,91354,81455,65153,60754,54154,59555,84953,69654,69351,67246,96438,80539,49339,99836,82836,81927,37027,80718,7600000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,112
29,773
28,176
26,332
49,772
47,389
43,613
39,762
49,860
45,985
40,098
34,094
27,971
168,600
204,850
199,803
199,228
184,430
165,517
145,417
125,140
102,696
79,080
57,940
34,874
18,742
14,083
9,308
383,045
386,571
390,079
393,631
0
784,731
785,571
786,454
787,255
788,099
1,147,129
1,491,156
1,492,766
0
0
0
0
00001,492,7661,491,1561,147,129788,099787,255786,454785,571784,7310393,631390,079386,571383,0459,30814,08318,74234,87457,94079,080102,696125,140145,417165,517184,430199,228199,803204,850168,60027,97134,09440,09845,98549,86039,76243,61347,38949,77226,33228,17629,77331,1120000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,759
27,807
27,371
36,819
36,828
39,998
39,493
38,805
46,965
51,672
54,693
53,696
55,850
54,594
54,541
53,607
55,651
54,814
37,913
37,395
37,557
36,978
36,366
35,753
35,817
35,661
35,235
47,675
46,558
47,190
51,419
50,331
50,434
49,386
48,681
47,990
48,362
46,801
42,472
42,027
40,183
39,128
38,489
37,295
55,111
8,485
8,320
7,710
7,126
5,126
1,746
1,247
2,313
894
641
641
7,492
4,337
6,293
2,530
3,074
2,031
141,578
161,594
17,725
17,725
16,141
2,253
0
02,25316,14117,72517,725161,594141,5782,0313,0742,5306,2934,3377,4926416418942,3131,2471,7465,1267,1267,7108,3208,48555,11137,29538,48939,12840,18342,02742,47246,80148,36247,99048,68149,38650,43450,33151,41947,19046,55847,67535,23535,66135,81735,75336,36636,97837,55737,39537,91354,81455,65153,60754,54154,59455,85053,69654,69351,67246,96538,80539,49339,99836,82836,81927,37127,80718,7590000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,913
37,396
37,557
36,978
36,366
35,754
35,817
35,225
34,556
46,754
46,540
44,847
48,565
47,572
47,267
46,259
45,252
44,244
43,919
42,895
41,872
40,849
39,825
38,802
37,779
36,755
54,297
6,006
6,006
5,507
5,008
4,509
1,746
1,247
2,494
641
641
641
0
4,026
4,026
2,530
0
2,031
6,027
31,822
0
0
0
0
0
0000031,8226,0272,03102,5304,0264,02606416416412,4941,2471,7464,5095,0085,5076,0066,00654,29736,75537,77938,80239,82540,84941,87242,89543,91944,24445,25246,25947,26747,57248,56544,84746,54046,75434,55635,22535,81735,75436,36636,97837,55737,39637,9130000000000000000000000000000000000000
> Total Stockholder Equity
33
144
132
87
78
72
63
10
6,960
4,915
1,794
14,824
11,949
9,223
5,574
18,207
16,278
14,416
15,055
23,081
40,904
70,755
64,913
57,768
49,271
39,654
30,886
15,380
3,924
26,435
16,600
6,903
-3,192
-14,117
35,004
20,351
13,515
20,053
27,055
10,900
81,060
69,234
51,190
48,854
31,681
11,144
-3,486
-19,991
66,748
55,299
39,940
41,352
37,545
50,229
31,799
42,999
29,472
9,920
-11,992
-32,481
-58,499
58,165
72,389
208,366
265,064
254,925
239,738
248,887
260,047
260,052
245,353
91,765
58,042
105,577
98,988
151,047
67,595
119,748
281,674
196,953
260,256
293,171
96,991
169,798
65,850
151,033
249,181
83,808
83,808249,181151,03365,850169,79896,991293,171260,256196,953281,674119,74867,595151,04798,988105,57758,04291,765245,353260,052260,047248,887239,738254,925265,064208,36672,38958,165-58,499-32,481-11,9929,92029,47242,99931,79950,22937,54541,35239,94055,29966,748-19,991-3,48611,14431,68148,85451,19069,23481,06010,90027,05520,05313,51520,35135,004-14,117-3,1926,90316,60026,4353,92415,38030,88639,65449,27157,76864,91370,75540,90423,08115,05514,41616,27818,2075,5749,22311,94914,8241,7944,9156,960106372788713214433
   Common Stock
1
2
2
2
2
2
2
8
39
39
40
49
50
50
50
60
61
62
64
69
72
76
77
78
80
80
81
82
83
90
91
92
92
92
100
101
102
104
104
104
112
113
113
113
113
113
114
115
124
125
125
126
127
128
128
128
129
129
129
130
130
142
142
143
144
144
145
145
145
146
147
137
135
137
135
135
143
142
141
138
138
138
135
135
132
132
132
127
127132132132135135138138138141142143135135137135137147146145145145144144143142142130130129129129128128128127126125125124115114113113113113113112104104104102101100929292919083828180807877767269646261605050504940393982222221
   Retained Earnings 
-30
-46
-59
-105
-115
-121
-130
-184
-5,265
-7,340
-10,593
-13,072
-16,265
-19,133
-22,834
-26,347
-29,837
-33,070
-36,721
-41,099
-44,457
-49,258
-56,287
-64,995
-74,949
-85,952
-96,824
-113,650
-128,375
-145,435
-159,345
-172,010
-183,798
-195,949
-208,358
-225,252
-234,888
-231,771
-226,606
-245,022
-260,141
-274,162
-294,168
-298,574
-317,862
-340,774
-360,066
-382,052
-408,600
-424,873
-445,153
-450,427
-465,535
-462,516
-486,976
-482,658
-502,135
-529,010
-557,955
-585,342
-618,239
-649,002
-646,253
-522,371
-478,569
-501,461
-529,311
-531,438
-529,642
-544,266
-569,281
-603,678
-609,781
-583,964
-547,757
-474,593
-433,725
-342,267
-125,682
-58,912
1,196
23,881
85,515
143,217
65,694
140,448
222,285
90,550
90,550222,285140,44865,694143,21785,51523,8811,196-58,912-125,682-342,267-433,725-474,593-547,757-583,964-609,781-603,678-569,281-544,266-529,642-531,438-529,311-501,461-478,569-522,371-646,253-649,002-618,239-585,342-557,955-529,010-502,135-482,658-486,976-462,516-465,535-450,427-445,153-424,873-408,600-382,052-360,066-340,774-317,862-298,574-294,168-274,162-260,141-245,022-226,606-231,771-234,888-225,252-208,358-195,949-183,798-172,010-159,345-145,435-128,375-113,650-96,824-85,952-74,949-64,995-56,287-49,258-44,457-41,099-36,721-33,070-29,837-26,347-22,834-19,133-16,265-13,072-10,593-7,340-5,265-184-130-121-115-105-59-46-30
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
251,721
253,558
255,818
341,089
343,284
345,245
347,315
349,459
351,843
356,450
361,930
475,249
480,044
485,014
491,694
502,980
512,657
518,647
525,628
531,390
538,585
545,751
552,737
559,659
707,086
718,553
731,044
744,359
756,978
769,382
780,457
789,483
803,782
814,095
695,066
667,677
688,318
646,184
625,483
501,186
461,897
407,229
256,347
261,713
271,169
13,177
27,368
0
12,068
0
0
0012,068027,36813,177271,169261,713256,347407,229461,897501,186625,483646,184688,318667,677695,066814,095803,782789,483780,457769,382756,978744,359731,044718,553707,086559,659552,737545,751538,585531,390525,628518,647512,657502,980491,694485,014480,044475,249361,930356,450351,843349,459347,315345,245343,284341,089255,818253,558251,7210000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
62
189
189
190
190
191
192
186
12,185
12,475
12,640
28,179
28,546
28,750
28,839
45,026
46,640
48,066
52,346
64,816
86,078
120,849
122,188
123,719
125,386
126,998
129,381
130,991
134,547
174,462
178,906
182,267
184,310
185,880
247,767
250,179
253,286
256,993
259,063
261,564
347,047
349,514
351,750
353,995
356,171
358,842
363,805
369,596
483,185
488,450
493,824
500,872
512,550
522,533
528,630
535,847
542,081
549,695
557,240
564,650
572,092
720,076
732,047
744,484
744,489
757,242
784,592
796,419
806,364
821,386
832,383
706,048
678,485
688,318
646,184
625,483
501,186
461,897
407,229
256,347
261,713
271,169
13,177
27,368
24
12,068
25,537
2,409
2,40925,53712,0682427,36813,177271,169261,713256,347407,229461,897501,186625,483646,184688,318678,485706,048832,383821,386806,364796,419784,592757,242744,489744,484732,047720,076572,092564,650557,240549,695542,081535,847528,630522,533512,550500,872493,824488,450483,185369,596363,805358,842356,171353,995351,750349,514347,047261,564259,063256,993253,286250,179247,767185,880184,310182,267178,906174,462134,547130,991129,381126,998125,386123,719122,188120,84986,07864,81652,34648,06646,64045,02628,83928,75028,54628,17912,64012,47512,18518619219119019018918962



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue829,253
Cost of Revenue-192,361
Gross Profit636,892636,892
 
Operating Income (+$)
Gross Profit636,892
Operating Expense-299,318
Operating Income337,574337,574
 
Operating Expense (+$)
Research Development76,363
Selling General Administrative149,182
Selling And Marketing Expenses0
Operating Expense299,318225,545
 
Net Interest Income (+$)
Interest Income0
Interest Expense-18,762
Other Finance Cost-0
Net Interest Income-18,762
 
Pretax Income (+$)
Operating Income337,574
Net Interest Income-18,762
Other Non-Operating Income Expenses0
Income Before Tax (EBT)348,329308,057
EBIT - interestExpense = 318,812
348,329
300,356
Interest Expense18,762
Earnings Before Interest and Taxes (EBIT)337,574367,091
Earnings Before Interest and Taxes (EBITDA)422,430
 
After tax Income (+$)
Income Before Tax348,329
Tax Provision-66,735
Net Income From Continuing Ops281,594281,594
Net Income281,594
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses491,679
Total Other Income/Expenses Net29,51718,762
 

Technical Analysis of Halozyme
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Halozyme. The general trend of Halozyme is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Halozyme's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Halozyme Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 42.64 < 42.82 < 43.33.

The bearish price targets are: 39.69 > 38.29 > 36.94.

Tweet this
Halozyme Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Halozyme Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Halozyme Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Halozyme Therapeutics Inc. The current macd is 0.57623115.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Halozyme price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Halozyme. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Halozyme price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Halozyme Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartHalozyme Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Halozyme Therapeutics Inc. The current adx is 33.60.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Halozyme shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Halozyme Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Halozyme Therapeutics Inc. The current sar is 42.10.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Halozyme Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Halozyme Therapeutics Inc. The current rsi is 57.49. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Halozyme Therapeutics Inc Daily Relative Strength Index (RSI) ChartHalozyme Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Halozyme Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Halozyme price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Halozyme Therapeutics Inc Daily Stochastic Oscillator ChartHalozyme Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Halozyme Therapeutics Inc. The current cci is -40.20417895.

Halozyme Therapeutics Inc Daily Commodity Channel Index (CCI) ChartHalozyme Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Halozyme Therapeutics Inc. The current cmo is 11.21.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Halozyme Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartHalozyme Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Halozyme Therapeutics Inc. The current willr is -64.74576271.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Halozyme is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Halozyme Therapeutics Inc Daily Williams %R ChartHalozyme Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Halozyme Therapeutics Inc. The current atr is 1.11765966.

Halozyme Therapeutics Inc Daily Average True Range (ATR) ChartHalozyme Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Halozyme Therapeutics Inc. The current obv is 8,431,504.

Halozyme Therapeutics Inc Daily On-Balance Volume (OBV) ChartHalozyme Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Halozyme Therapeutics Inc. The current mfi is 44.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Halozyme Therapeutics Inc Daily Money Flow Index (MFI) ChartHalozyme Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Halozyme Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Halozyme Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Halozyme Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.488
Ma 20Greater thanMa 5040.882
Ma 50Greater thanMa 10037.825
Ma 100Greater thanMa 20037.923
OpenGreater thanClose40.510
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Halozyme with someone you think should read this too:
  • Are you bullish or bearish on Halozyme? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Halozyme? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Halozyme Therapeutics Inc

I send you an email if I find something interesting about Halozyme Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Halozyme Therapeutics Inc.

Receive notifications about Halozyme Therapeutics Inc in your mailbox!